Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-25-080447
Filing Date
2025-08-20
Accepted
2025-08-20 06:00:32
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 26549
2 EXHIBIT 99.1 tm2523856d2_ex99-1.htm EX-99.1 18096
3 GRAPHIC tm2523856d2_ex99-1img01.jpg GRAPHIC 3298
4 GRAPHIC tm2523856d2_ex99-1img02.jpg GRAPHIC 18831
  Complete submission text file 0001104659-25-080447.txt   77146
Mailing Address ZERNIKEDREEF 9 LEIDEN P7 2333 CK
Business Address ZERNIKEDREEF 9 LEIDEN P7 2333 CK 31 88 166 7000
ProQR Therapeutics N.V. (Subject) CIK: 0001612940 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-88671 | Film No.: 251233724
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address LICHTENAUERLAAN 30 ROTTERDAM P7 3062ME
Business Address LICHTENAUERLAAN 30 ROTTERDAM P7 3062ME 0031102411555
VAN HERK INVESTMENTS B.V. (Filed by) CIK: 0001633120 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A